Forte Capital LLC ADV Buys 93 Shares of Stryker Co. (NYSE:SYK)

Forte Capital LLC ADV boosted its position in shares of Stryker Co. (NYSE:SYK) by 1.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 5,407 shares of the medical technology company’s stock after acquiring an additional 93 shares during the period. Forte Capital LLC ADV’s holdings in Stryker were worth $1,953,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the company. Two Point Capital Management Inc. increased its holdings in Stryker by 1.1% in the 3rd quarter. Two Point Capital Management Inc. now owns 21,833 shares of the medical technology company’s stock valued at $7,887,000 after buying an additional 245 shares during the period. Consilium Wealth Advisory LLC acquired a new stake in shares of Stryker during the 3rd quarter valued at about $512,000. Gordian Advisors LLC bought a new stake in Stryker in the third quarter valued at about $298,000. Umpqua Bank raised its position in Stryker by 0.7% in the third quarter. Umpqua Bank now owns 5,369 shares of the medical technology company’s stock worth $1,940,000 after purchasing an additional 39 shares in the last quarter. Finally, Ballast Advisors LLC boosted its holdings in Stryker by 2.1% during the third quarter. Ballast Advisors LLC now owns 3,075 shares of the medical technology company’s stock valued at $1,111,000 after purchasing an additional 62 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Trading Down 0.2 %

Shares of NYSE SYK opened at $369.02 on Thursday. Stryker Co. has a fifty-two week low of $266.93 and a fifty-two week high of $376.04. The firm has a market capitalization of $140.68 billion, a P/E ratio of 39.55, a P/E/G ratio of 2.77 and a beta of 0.91. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.91 and a quick ratio of 1.22. The company’s 50 day simple moving average is $360.91 and its 200 day simple moving average is $345.12.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.77 by $0.10. The business had revenue of $5.49 billion for the quarter, compared to analyst estimates of $5.37 billion. Stryker had a return on equity of 23.07% and a net margin of 16.34%. The firm’s revenue was up 11.9% on a year-over-year basis. During the same period last year, the company earned $2.46 EPS. On average, analysts predict that Stryker Co. will post 12.06 EPS for the current year.

Insider Activity at Stryker

In related news, VP M Kathryn Fink sold 7,347 shares of the business’s stock in a transaction that occurred on Tuesday, September 17th. The shares were sold at an average price of $366.98, for a total transaction of $2,696,202.06. Following the completion of the transaction, the vice president now owns 10,042 shares in the company, valued at approximately $3,685,213.16. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, insider Viju Menon sold 600 shares of Stryker stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $355.00, for a total transaction of $213,000.00. Following the transaction, the insider now owns 9,069 shares in the company, valued at $3,219,495. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP M Kathryn Fink sold 7,347 shares of the stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $366.98, for a total value of $2,696,202.06. Following the sale, the vice president now directly owns 10,042 shares of the company’s stock, valued at approximately $3,685,213.16. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 10,068 shares of company stock worth $3,693,972 in the last ninety days. Company insiders own 5.50% of the company’s stock.

Analyst Ratings Changes

SYK has been the subject of a number of recent research reports. UBS Group increased their target price on Stryker from $366.00 to $370.00 and gave the stock a “neutral” rating in a report on Wednesday, October 30th. Evercore ISI lifted their price objective on Stryker from $380.00 to $384.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. Truist Financial upped their target price on shares of Stryker from $370.00 to $380.00 and gave the stock a “hold” rating in a report on Wednesday, October 30th. Barclays lifted their price target on shares of Stryker from $402.00 to $418.00 and gave the company an “overweight” rating in a report on Thursday, October 31st. Finally, Wolfe Research began coverage on shares of Stryker in a report on Tuesday, September 10th. They set an “outperform” rating and a $405.00 price objective for the company. Five investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $393.65.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.